There is a significant difference between listing events and proving business performance. Your post relies heavily on procedural milestones while omitting critical context. Let’s separate regulatory survival from operational success.
1. Digital Clarity Acquisition (2011–2012)
Yes, DBMM acquired Digital Clarity around 2011/2012.
However:
Digital Clarity was already an existing UK digital marketing firm.
The acquisition did not produce sustained revenue growth, profitability, or shareholder value over the following decade.
DBMM has remained a microcap OTC issuer with chronic dilution and minimal scale relative to public market standards.
An acquisition alone is not evidence of execution.
2. Re-Audit (2013–2014)
The post frames the re-audit as “through no fault of DBMM.”
Context:
When a public company undergoes a 3-year re-audit, it signals accounting, reporting, or auditor-related complications.
The cost of $157,300 is not extraordinary for a multi-year audit.
Completing required filings is compliance — not a strategic victory.
Compliance with SEC reporting requirements is the minimum standard, not an achievement.
3. Asher Litigation (2014–2018)
The settlement with Asher Enterprises is portrayed as a 50% discount win.
Important omitted facts:
Asher was a convertible note holder.
Convertible debt financing is highly dilutive and often associated with toxic financing structures.
The existence of litigation itself reflects capital structure stress.
Canceling CDs after settlement does not undo prior dilution impact.
Convertible note cycles are not indicators of strong corporate finance health.
4. Administrative Proceeding & SEC Dismissal
The Administrative Proceeding began May 16, 2017 due to delinquent filings.
Key points:
The proceeding existed because the company was not timely in required filings.
The ALJ dismissal and final SEC dismissal (June 2, 2023) did not constitute endorsement of the company.
The dismissal effectively allowed the company to remain registered rather than be revoked.
An SEC dismissal in this context is procedural — not validation of business performance or financial strength.
Survival ? success.
5. “Late filings cured” (May 31, 2018)
Curing filings restores compliance.
It does not:
Increase revenue
Increase margins
Eliminate dilution
Demonstrate operational scale
It merely restores reporting status.
6. CE Removal & PPS Move to $0.039 (12/21/22)
Yes, the CE (Caveat Emptor) designation was removed.
However:
CE removal reflects updated disclosures, not business growth.
The price move to $0.039 was temporary and driven by speculative trading surrounding regulatory resolution.
Long-term price stability and sustained growth did not follow.
Short-term volatility around regulatory events is common in OTC microcaps.
7. “All metrics up”
This claim requires financial proof.
Questions investors should ask:
What are annual revenues over the last 5 years?
Are they growing consistently?
Is the company cash-flow positive?
What is operating margin?
What is net income?
What is outstanding share count trend?
How much dilution has occurred since 2014?
Without audited, multi-year growth data, “all metrics up” is marketing language — not analysis.
8. Uplist to QB ? NASDAQ
Reality check:
To uplist to NASDAQ, a company must meet:
Minimum bid price requirements
Shareholder equity thresholds
Net income or market value of publicly held shares thresholds
Corporate governance standards
Independent directors
Audit committee requirements
There has been no demonstrated financial scale suggesting near-term NASDAQ eligibility.
Speculating on NASDAQ without meeting measurable listing standards is premature.
9. “Strategic Alliances” and Client Announcements
Claims listed:
Austin software client
Irvine representation
Xamun partnership (Nov 2025)
Conference presentation (Oct 31, 2024)
Strategic Alliance #12
Missing from the post:
Revenue contribution from each alliance
Contract values
Duration of agreements
Conversion rate from alliance to booked revenue
Margin impact
Announcements without disclosed financial impact are PR — not proof of scalable growth.
10. The Core Issue
The post emphasizes:
Litigation survival
Regulatory dismissal
Filing compliance
Partnerships
Presentations
It does not demonstrate:
Sustained revenue growth trajectory
Profitability
Strong balance sheet
Reduction in dilution
Measurable shareholder return over 10+ years
A company can:
Avoid revocation
Cure filings
Settle litigation
Issue PRs
Present at conferences
… and still fail to build shareholder value.
11. “The Company knows exactly what it is doing.”
If that were demonstrably true, we would expect to see:
Clear, multi-year revenue expansion
Stable capital structure
Reduced dilution
Uplist execution
Institutional ownership growth
Stronger market capitalization trend
Instead, DBMM has spent more than a decade largely focused on regulatory survival and financing cycles.
Bottom Line
The narrative being pushed equates regulatory survival with corporate success.
They are not the same.
The critical questions remain:
Has DBMM created sustained shareholder value since 2012?
Has revenue growth materially accelerated?
Has dilution stopped?
Is profitability consistent and meaningful?
Investors should focus on audited financial performance and capital structure — not milestone lists framed as victories.
Compliance is required.
Execution is optional.
Performance is measurable.
Only one of those ultimately matters.
Market Data 
Markets 
